MTOR and ovarian cancer: In ovarian cancer, BEZ235 significantly prevents hypoxia- and TGF-β1-induced EMT and up-regulates the E-cadherin expression in vitro and in vivo, suggesting that dual inhibition of AKT and mTOR may have the potential for treatment of cancer metastasis (48).